Literature DB >> 10930686

Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents.

L G Rudenko1, N H Arden, E Grigorieva, A Naychin, A Rekstin, A I Klimov, S Donina, J Desheva, R C Holman, A DeGuzman, N J Cox, J M Katz.   

Abstract

The immunogenicity and efficacy of Russian live attenuated and US inactivated trivalent influenza vaccines administered alone or in three different combinations were evaluated in a randomized, placebo-controlled, double-blinded study of 614 elderly or chronically ill nursing home residents in St. Petersburg, Russia during the 1996-97 influenza season. Postvaccination serum antibody responses were more frequent among individuals administered the combination vaccines than among those vaccinated with live or inactivated vaccine alone. Only individuals who received live vaccine, alone or in combination with inactivated vaccine, achieved significant postvaccination increases in virus-specific nasal IgA. Efficacy in preventing laboratory-confirmed influenza in vaccinated versus nonvaccinated individuals was 67% (95%CI, 36-81%) for recipients of a combination of the vaccines compared with 51% (95%CI, -17-79%) for recipients of live vaccine alone and 50% (95%CI, -26-80%) for recipients of inactivated vaccine alone. These results suggest that administration of a combination of influenza vaccines may provide a strategy for improved influenza vaccination of elderly people.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930686     DOI: 10.1016/s0264-410x(00)00153-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

2.  Stockpile, use during outbreaks, restock, repeat.

Authors:  Michael R Kolber; Christina Korownyk
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

Review 3.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

4.  Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Authors:  Lidia Brydak; Julie Roiz; Pascaline Faivre; Camille Reygrobellet
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

Review 5.  Influenza vaccination in the elderly: impact on hospitalisation and mortality.

Authors:  Kristin L Nichol
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Authors:  Lisa A Jackson; Manjusha J Gaglani; Harry L Keyserling; John Balser; Nancy Bouveret; Louis Fries; John J Treanor
Journal:  BMC Infect Dis       Date:  2010-03-17       Impact factor: 3.090

Review 7.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

8.  The imperative of influenza vaccines for elderly individuals-an evolving story.

Authors:  Gregory A Poland; Mark J Mulligan
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

Review 9.  A systematic mapping review of randomized controlled trials (RCTs) in care homes.

Authors:  Adam L Gordon; Phillipa A Logan; Rob G Jones; Calum Forrester-Paton; Jonathan P Mamo; John R F Gladman
Journal:  BMC Geriatr       Date:  2012-06-25       Impact factor: 3.921

10.  Confronting potential influenza A (H5N1) pandemic with better vaccines.

Authors:  Azizul Haque; Didier Hober; Lloyd H Kasper
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.